EGFR and hepatocellular carcinoma: It suggested that some RTKs inhibitors sorafenib, tended to be effective to primary HCC mass by interruption of neoplastic angiogenesis, but low expression of VEGFR/PDGFRβ or compensation effect from EGFR/MET in HCC cell lines were invalid in metastasis.